Sanjivani Paranteral Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹21Cr
- +20.2% YoY
- +34.6% QoQ
- Net profit
- ₹3Cr
- +37.9% YoY
- +59.8% QoQ
- Margin
- 17.26%
- +2.6 pp YoY
- +2.7 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Sanjivani Paranteral Ltd Q3 FY26 key numbers
- Revenue
- SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
As stated in Sanjivani Paranteral Ltd's Q3 FY26 earnings call transcript · published 14 Aug 2026. Reported figures, not investment advice.
The short version
FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).
From Sanjivani Paranteral Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
- SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
- Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
- Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
- Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
- Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
- Export markets to continue being key revenue drivers, contributing ~77% of total revenue.
2 more points from Sanjivani Paranteral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major capex cycle is currently over; all plants are operational.
- FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
- No significant new capex expected in FY '27 beyond this recurring amount.
- Future growth is expected from ramp-up and approvals rather than large new investments.
2 more points from Sanjivani Paranteral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It indicates strong growth driven primarily by export markets and product mix improvements.
- The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
- The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
- Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28.
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Sanjivani Paranteral Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 21 | 17 | +20.2% | 16 | +34.6% |
| Operating profit (EBITDA) | 4 | 3 | +41.2% | 2 | +60% |
| Operating margin | 17.26% | 14.7% | +2.6 pp | 14.52% | +2.7 pp |
| Profit before tax | 3 | 3 | +39% | 2 | +59.4% |
| Net profit (PAT) | 3 | 2 | +37.9% | 2 | +59.8% |
| EPS (₹) | 2.13 | 1.60 | +33.1% | 1.34 | +59% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjivani Paranteral's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanjivani Paranteral Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q3 FY26 results?
FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
Major capex cycle is currently over; all plants are operational.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
